Semaphorin 3A causes immune suppression by inducing cytoskeletal paralysis in tumour-specific CD8+ T cells
Mike B. Barnkob,Yale S. Michaels,Violaine André,Philip S. Macklin,Uzi Gileadi,Salvatore Valvo,Margarida Rei,Corinna Kulicke,Ji-Li Chen,Vitul Jain,Victoria K. Woodcock,Huw Colin-York,Andreas V. Hadjinicolaou,Youxin Kong,Viveka Mayya,Julie M. Mazet,Gracie-Jennah Mead,Joshua A. Bull,Pramila Rijal,Christopher W. Pugh,Alain R. Townsend,Audrey Gérard,Lars R. Olsen,Marco Fritzsche,Tudor A. Fulga,Michael L. Dustin,E. Yvonne Jones,Vincenzo Cerundolo
DOI: https://doi.org/10.1038/s41467-024-47424-z
IF: 16.6
2024-04-12
Nature Communications
Abstract:Abstract Semaphorin-3A (SEMA3A) functions as a chemorepulsive signal during development and can affect T cells by altering their filamentous actin (F-actin) cytoskeleton. The exact extent of these effects on tumour-specific T cells are not completely understood. Here we demonstrate that Neuropilin-1 (NRP1) and Plexin-A1 and Plexin-A4 are upregulated on stimulated CD8 + T cells, allowing tumour-derived SEMA3A to inhibit T cell migration and assembly of the immunological synapse. Deletion of NRP1 in both CD4 + and CD8 + T cells enhance CD8 + T-cell infiltration into tumours and restricted tumour growth in animal models. Conversely, over-expression of SEMA3A inhibit CD8 + T-cell infiltration. We further show that SEMA3A affects CD8 + T cell F-actin, leading to inhibition of immune synapse formation and motility. Examining a clear cell renal cell carcinoma patient cohort, we find that SEMA3A expression is associated with reduced survival, and that T-cells appear trapped in SEMA3A rich regions. Our study establishes SEMA3A as an inhibitor of effector CD8 + T cell tumour infiltration, suggesting that blocking NRP1 could improve T cell function in tumours.
multidisciplinary sciences